# Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

> **NCT02367547** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Joint Authority for Päijät-Häme Social and Health Care** · enrollment: 117 (actual)

## Conditions studied

- Neoplasms, Basal Cell
- Carcinoma, Basal Cell
- Photochemotherapy
- Photosensitizing Agents

## Interventions

- **DRUG:** Hexylaminolevulinate cream
- **DRUG:** Aminolevulinic Acid Nano Emulsion
- **DRUG:** Methylaminolevulinate cream

## Key facts

- **NCT ID:** NCT02367547
- **Lead sponsor:** Joint Authority for Päijät-Häme Social and Health Care
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2018-09
- **Final completion:** 2025-12
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2019-03-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367547, "Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02367547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*